Randomized controlled study comparing the use of diphencyprone and anthralin in the treatment of extensive chronic alopecia areata

Rocha, Vanessa Barreto; Kakizaki, Priscila; Donati, Aline; Machado, Carla Jorge; Pires, Mário Cézar; Contin, Letícia Arsie

doi:10.1016/j.abd.2020.06.018

Cited by 6 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Die berichteten Ansprechraten bei umschriebener AA liegen bei 75 % [129] und bei ausgeprägter AA und AT zwischen 18 % und 37 %. [127,130,131]. Darüber hinaus wurde in einer Studie bei Kindern mit AA berichtet, dass in 33 % der Fälle die Haare vollständig nachwuchsen [132].…”

Section: Topische Reiztherapieunclassified

See 1 more Smart Citation

Alopecia areata – Aktuelles Verständnis und Management

Lintzeri

Constantinou

Hillmann

et al. 2022

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Die Alopecia areata (AA) ist eine chronische immunvermittelte Erkrankung, die durch akuten oder chronischen, nicht vernarbenden Haarausfall gekennzeichnet ist. Die klinischen Erscheinungsformen sind sehr unterschiedlich und reichen von kleinen umschriebenen haarlosen Stellen bis hin zum vollständigen Verlust der Kopf-und Körperbehaarung. Diese Übersicht soll aktuelles Wissen zu Pathophysiologie und beteiligten Signalwegen vermitteln sowie diagnostische und therapeutische Empfehlungen geben. Aktuell verfügbare Therapieansätze bei AA, einschließlich topischer, systemischer und injizierbarer Interventionen, zeigen unterschiedlich gutes Ansprechen mit häufigen Rezidiven, was den dringenden Bedarf an effektiven zielgerichteten Therapien widerspiegelt. Neue therapeutische Ansätze und Konzepte, einschließlich Januskinase-Inhibitoren, werden mit großer Spannung erwartet. Diese Übersicht diskutiert traditionelle und neue Therapieansätze für das Management der AA. Diese Erkrankung führt häufig zu einer starken psychosozialen Belastung für die Betroffenen, kann zu Depressionen führen, Angstzustände auslösen und die Lebensqualität beeinträchtigen. Daher sollten psychosoziale Aspekte der Krankheit mit berücksichtigt, beim Patienten angesprochen und die Notwendigkeit einer psychologischen Unterstützung erwogen werden.

show abstract

Section: Topische Reiztherapieunclassified

“…Dithranol-induzierte, gering-mittelgradige Dermatitis verschwunden ist. Ein Ansprechen ist in der Regel nach 3-4 Monaten zu beobachten [127,128]. In diesem Fall sollte die Behandlung länger fortgesetzt werden.…”

Section: Topische Reiztherapieunclassified

Alopecia areata – Aktuelles Verständnis und Management

Lintzeri

Constantinou

Hillmann

et al. 2022

J Deutsche Derma Gesell

View full text Add to dashboard Cite

show abstract

“…Response is usually seen after 3-4 months [127,128]; in that case treatment should continue for longer. There are only a few studies on the efficacy of anthralin as monotherapy; the response rates reported in patchy AA are 75 % [129], and in severe AA and AT range from 18-37 % [127,130,131]. Moreover, a study on children with AA reported complete hair regrowth in 33 % of the cases [132].…”

Section: Topical Irritation Therapymentioning

confidence: 99%

“…Escalation of dosage or time is performed once the anthralin-induced mild dermatitis has resolved. Response is usually seen after 3-4 months [127,128]; in that case treatment should continue for longer. There are only a few studies on the efficacy of anthralin as monotherapy; the response rates reported in patchy AA are 75 % [129], and in severe AA and AT range from 18-37 % [127,130,131].…”

Section: Topical Irritation Therapymentioning

confidence: 99%

Alopecia areata – Current understanding and management

Lintzeri

Constantinou

Hillmann

et al. 2022

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Alopecia areata (AA) is a chronic, immune-mediated disease characterized by acute or chronic non-scarring hair loss, with a heterogeneity in clinical manifestations ranging from patchy hair loss to complete scalp and body hair loss. An overview of the up-to-date pathophysiology and the underlying signaling pathways involved in AA together with diagnostic and therapeutic recommendations will be provided. Current treatments, including topical, systemic and injectable interventions show varying response and frequent relapses reflecting the unmet clinical need. Thus, the new emerging concepts and therapeutic approaches, including Janus kinase inhibitors are eagerly awaited. Traditional and emerging therapies of AA will be discussed, in order to provide physicians with guidance for AA management. Since the latter is so challenging and often tends to take a chronic course, it can have an enormous psychosocial burden on patients, compromising their quality of life and often causing depression and anxiety. Therefore, the psychosocial aspects of the disease need to be evaluated and addressed, in order to implement appropriate psychological support when needed.

show abstract

“…Other topical treatments include anthralin as a topical irritation therapy, contact sensitizers as squaric acid dibutylester, topical retinoids, topical calcineurin inhibitors, topical vitamin D analogue, prostaglandin analogs, platelet-rich plasma and cryotherapy (8) .…”

Section: Introductionmentioning

confidence: 99%

Brief Treatment Modalities of Alopecia Areata: Review Article

Fattah¹,

Mokadem²,

Ghonemy³

2022

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Hair loss on the scalp and/or body due to Alopecia Areata (AA) is a frequent autoimmune, inflammatory, nonscarring form of baldness. Hair loss can occur in a variety of patterns, from thinning in discrete areas to a complete loss of hair from follicle. All treatments of AA are considered off-label. While these therapies may help stimulate hair growth, they are not considered curative because they cannot alter the disease's normal progression. Age, general health, and the severity of hair loss all play a role in determining the best course of therapy. Objective: Assessment of current treatment modalities of alopecia areata. Methods: Treatment, and alopecia areata were all looked for in PubMed, Google scholar, and Science direct. References from relevant literature were also evaluated by the authors, but only the most recent or complete study from September 2007 to May 2021 was included. Due to the lack of sources for translation, documents in languages other than English have been ruled out. Papers that did not fall under the purview of major scientific investigations, such as unpublished manuscripts, oral presentations, conference abstracts, and dissertations, were omitted. Conclusion: Because of their low risk of adverse effects and simple administration, topical corticosteroids of varying strengths are often the first line of defense in the treatment of AA in children. In more advanced cases of AA, systemic therapies are performed. Most of these drugs work by modulating or suppressing the immune system.

show abstract

Randomized controlled study comparing the use of diphencyprone and anthralin in the treatment of extensive chronic alopecia areata

Cited by 6 publications

References 11 publications

Alopecia areata – Aktuelles Verständnis und Management

Alopecia areata – Aktuelles Verständnis und Management

Alopecia areata – Current understanding and management

Brief Treatment Modalities of Alopecia Areata: Review Article

Contact Info

Product

Resources

About